{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(2)"],"submitter":["Koskinas J"],"pubmed_abstract":["<h4>Background</h4>Newer advances involving immunotherapies are changing the hepatocellular carcinoma (HCC) landscape. In the multinational OPAL study, we described the characteristics of patients with HCC during 2014-2021 in Greece.<h4>Methods</h4>This was a retrospective chart review study of adults (alive/dead) with newly diagnosed HCC between 2014-2021.<h4>Results</h4>Of 406 patients, 37.7%, 33.0%, 25.9% and 3.4% had Barcelona Clinic Liver Cancer (BCLC) stage 0/A, B, C and D, respectively. Common etiologies were hepatitis B virus (32.9%), alcohol use (31.6%), hepatitis C virus (27.6%), and metabolic dysfunction-associated steatotic liver disease (26.3%); viral+non-viral: 15.5%. The first treatment was resection, embolization, ablation, systemic therapy and transplant, in 35.5%, 30.7%, "],"journal":["Annals of gastroenterology"],"pagination":["195-207"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11928893"],"repository":["biostudies-literature"],"pubmed_title":["Treatment patterns and outcomes in hepatocellular carcinoma: Real-world experience in Greece from the retrospective OPAL study."],"pmcid":["PMC11928893"],"pubmed_authors":["Alexopoulou A","Papagiouvanni I","Manolakopoulos S","Goulis I","Drygiannakis I","Koskinas J","Koutroubakis I","Michailidou E","Magafouraki E","Elefsiniotis I","Papatheodoridis G","Koullias E","Deutsch M","Kranidioti H","Pantzios S","Samonakis D","Tsaliki E"],"additional_accession":[]},"is_claimable":false,"name":"Treatment patterns and outcomes in hepatocellular carcinoma: Real-world experience in Greece from the retrospective OPAL study.","description":"<h4>Background</h4>Newer advances involving immunotherapies are changing the hepatocellular carcinoma (HCC) landscape. In the multinational OPAL study, we described the characteristics of patients with HCC during 2014-2021 in Greece.<h4>Methods</h4>This was a retrospective chart review study of adults (alive/dead) with newly diagnosed HCC between 2014-2021.<h4>Results</h4>Of 406 patients, 37.7%, 33.0%, 25.9% and 3.4% had Barcelona Clinic Liver Cancer (BCLC) stage 0/A, B, C and D, respectively. Common etiologies were hepatitis B virus (32.9%), alcohol use (31.6%), hepatitis C virus (27.6%), and metabolic dysfunction-associated steatotic liver disease (26.3%); viral+non-viral: 15.5%. The first treatment was resection, embolization, ablation, systemic therapy and transplant, in 35.5%, 30.7%, ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar-Apr","modification":"2025-07-11T03:03:58.966Z","creation":"2025-07-11T03:03:58.966Z"},"accession":"S-EPMC11928893","cross_references":{"pubmed":["40124433"],"doi":["10.20524/aog.2025.0950"]}}